ATE519755T1 - Modulatoren des vitamin-d-rezeptors - Google Patents
Modulatoren des vitamin-d-rezeptorsInfo
- Publication number
- ATE519755T1 ATE519755T1 AT05854993T AT05854993T ATE519755T1 AT E519755 T1 ATE519755 T1 AT E519755T1 AT 05854993 T AT05854993 T AT 05854993T AT 05854993 T AT05854993 T AT 05854993T AT E519755 T1 ATE519755 T1 AT E519755T1
- Authority
- AT
- Austria
- Prior art keywords
- modulators
- vitamin
- receptor
- secosteroidal
- zxb
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63802904P | 2004-12-21 | 2004-12-21 | |
PCT/US2005/046361 WO2006069154A2 (en) | 2004-12-21 | 2005-12-19 | Vitamin d receptor modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE519755T1 true ATE519755T1 (de) | 2011-08-15 |
Family
ID=36602286
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT05854993T ATE519755T1 (de) | 2004-12-21 | 2005-12-19 | Modulatoren des vitamin-d-rezeptors |
Country Status (11)
Country | Link |
---|---|
US (1) | US7659296B2 (de) |
EP (1) | EP1836177B1 (de) |
JP (1) | JP2008524260A (de) |
KR (1) | KR100931777B1 (de) |
AT (1) | ATE519755T1 (de) |
BR (1) | BRPI0519152A2 (de) |
CA (1) | CA2589667A1 (de) |
ES (1) | ES2369510T3 (de) |
IL (1) | IL183779A0 (de) |
MX (1) | MX2007007225A (de) |
WO (1) | WO2006069154A2 (de) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100471853C (zh) | 2002-05-29 | 2009-03-25 | 伊莱利利公司 | 苯基-噻吩型维生素d受体调节剂 |
BR0316401A (pt) | 2002-11-22 | 2006-02-21 | Lilly Co Eli | composto ou um sal farmaceuticamente aceitável ou um derivado de pró-droga de éster do mesmo, derivados de pró-droga e de sal de um composto, formulações farmacêutica, para tratar a osteoporose, e para tratar psorìase, métodos para tratar um mamìfero para prevenir ou aliviar os efeitos patológicos, para tratar ou previnir estados de doenças mediados pelo receptor de vitamimna d, e para tratar um mamìfero para prevenir ou aliviar o efeito de mostarda, processo para preparar um composto, e, uso de um composto |
EP1687265A2 (de) | 2003-11-20 | 2006-08-09 | Eli Lilly And Company | Modulatoren des vitamin-d-rezeptors |
ES2291981T3 (es) | 2003-11-20 | 2008-03-01 | Eli Lilly And Company | Moduladores del receptor de la vitamina d. |
JP4589337B2 (ja) | 2003-11-20 | 2010-12-01 | イーライ リリー アンド カンパニー | ビタミン受容体調節剤 |
JP4717005B2 (ja) | 2003-11-20 | 2011-07-06 | イーライ リリー アンド カンパニー | ビタミンd受容体モジュレータ |
JP2008524259A (ja) | 2004-12-21 | 2008-07-10 | イーライ リリー アンド カンパニー | ビタミンd受容体モジュレーター |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100471853C (zh) | 2002-05-29 | 2009-03-25 | 伊莱利利公司 | 苯基-噻吩型维生素d受体调节剂 |
BR0316401A (pt) * | 2002-11-22 | 2006-02-21 | Lilly Co Eli | composto ou um sal farmaceuticamente aceitável ou um derivado de pró-droga de éster do mesmo, derivados de pró-droga e de sal de um composto, formulações farmacêutica, para tratar a osteoporose, e para tratar psorìase, métodos para tratar um mamìfero para prevenir ou aliviar os efeitos patológicos, para tratar ou previnir estados de doenças mediados pelo receptor de vitamimna d, e para tratar um mamìfero para prevenir ou aliviar o efeito de mostarda, processo para preparar um composto, e, uso de um composto |
WO2004063345A2 (en) | 2003-01-10 | 2004-07-29 | Eli Lilly And Company | Vesicant treatment with phenyl-phenyl type vitamin d receptor modulators |
WO2004063348A2 (en) | 2003-01-10 | 2004-07-29 | Eli Lilly And Company | Vesicant treatment with phenyl-thiophene type vitamin d receptor modulators |
EP1687265A2 (de) | 2003-11-20 | 2006-08-09 | Eli Lilly And Company | Modulatoren des vitamin-d-rezeptors |
ES2291981T3 (es) | 2003-11-20 | 2008-03-01 | Eli Lilly And Company | Moduladores del receptor de la vitamina d. |
ATE396982T1 (de) | 2003-11-20 | 2008-06-15 | Lilly Co Eli | Phenylfuranverbindungen als modulatoren des vitamin-d-rezeptors |
JP4589337B2 (ja) | 2003-11-20 | 2010-12-01 | イーライ リリー アンド カンパニー | ビタミン受容体調節剤 |
JP4717005B2 (ja) | 2003-11-20 | 2011-07-06 | イーライ リリー アンド カンパニー | ビタミンd受容体モジュレータ |
JP2008524259A (ja) | 2004-12-21 | 2008-07-10 | イーライ リリー アンド カンパニー | ビタミンd受容体モジュレーター |
-
2005
- 2005-12-19 MX MX2007007225A patent/MX2007007225A/es active IP Right Grant
- 2005-12-19 KR KR1020077013993A patent/KR100931777B1/ko not_active IP Right Cessation
- 2005-12-19 US US11/721,676 patent/US7659296B2/en not_active Expired - Fee Related
- 2005-12-19 AT AT05854993T patent/ATE519755T1/de not_active IP Right Cessation
- 2005-12-19 CA CA002589667A patent/CA2589667A1/en not_active Abandoned
- 2005-12-19 EP EP05854993A patent/EP1836177B1/de active Active
- 2005-12-19 JP JP2007547045A patent/JP2008524260A/ja not_active Withdrawn
- 2005-12-19 WO PCT/US2005/046361 patent/WO2006069154A2/en active Application Filing
- 2005-12-19 BR BRPI0519152-1A patent/BRPI0519152A2/pt not_active IP Right Cessation
- 2005-12-19 ES ES05854993T patent/ES2369510T3/es active Active
-
2007
- 2007-06-07 IL IL183779A patent/IL183779A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP1836177B1 (de) | 2011-08-10 |
CA2589667A1 (en) | 2006-06-29 |
ES2369510T3 (es) | 2011-12-01 |
BRPI0519152A2 (pt) | 2008-12-30 |
US7659296B2 (en) | 2010-02-09 |
US20080119407A1 (en) | 2008-05-22 |
JP2008524260A (ja) | 2008-07-10 |
IL183779A0 (en) | 2007-09-20 |
WO2006069154A2 (en) | 2006-06-29 |
MX2007007225A (es) | 2007-08-21 |
KR20070086470A (ko) | 2007-08-27 |
KR100931777B1 (ko) | 2009-12-14 |
WO2006069154A3 (en) | 2006-12-21 |
EP1836177A2 (de) | 2007-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SE0301010D0 (sv) | Novel compounds | |
SE0301009D0 (sv) | Novel compounds | |
SG10201809390QA (en) | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | |
ATE433447T1 (de) | Pyrimiidinverbindungen | |
TW200612892A (en) | Novel compounds | |
EA200900048A1 (ru) | Новые карбонилированные (аза)циклогексаны в качестве лигандов d3 рецептора дофамина | |
SE0303180D0 (sv) | Novel compounds | |
MX2009005462A (es) | Analogos de 7,8-saturados-4,5-epoxi-morfinano. | |
SE0302232D0 (sv) | Novel Compounds | |
TW200612936A (en) | Indole derivatives | |
NO20070224L (no) | 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav | |
LT2006017A (en) | 2-(quinoxalin-5-ylsulfonylamino)-benzamide compounds as cck2 modulators | |
WO2003086306A3 (en) | 5ht2c receptor modulators | |
EA201001682A1 (ru) | Производные фенил- и бензодиоксинилзамещенных индазолов | |
EA200870193A1 (ru) | Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение | |
EA200702329A1 (ru) | Замещенные пирролпиридины, содержащие их композиции, способ получения и применение | |
TW200738659A (en) | Novel compounds | |
HK1113790A1 (en) | Selurampanel | |
BRPI0506477A (pt) | compostos farmaceuticamente úteis e inovadores | |
TW200833670A (en) | Novel compounds 569 | |
TW200745024A (en) | Carboxamide derivatives as muscarinic receptor antagonists | |
TW200745122A (en) | New compounds I | |
ATE519755T1 (de) | Modulatoren des vitamin-d-rezeptors | |
MX2009003981A (es) | Agentes moduladores del receptor de calcio. | |
TW200740781A (en) | Novel compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |